Specialty pharma ready to dispense Xtandi after expanded indication
- Xtandi (enzalutamide) has now been approved for treatment of metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy.
- Xtandi, an oral drug, is available via specialty pharmacies. It is now available for treatment of all stages of prostate cancer.
- Phase III trials show that men with mCRPC and other types of prostate cancer have significantly improved overall survival (OS) outcomes, as well as delayed time to radiographic progression or death compared with standard of care.
In September, BioPharma Dive reported on expanded use of Xtandi and the anticipated impact on sales—more than $2.7 billion in annual sales within the next four years, or even more. As an oral, once-daily androgen receptor inhibitor capsule, Xtandi provides an important treatment option for men with mCRPC regardless of whether they have already received treatment or not.
- Pharmaceutical Business Review FDA approves XTANDI to treat metastatic castration-resistant prostate cancer